Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Predicting Risk of Blood Clots in Brain Tumors
Clinical Breakthroughs

Predicting Risk of Blood Clots in Brain Tumors

By Olivia DimmerMar 16, 2023
Share
Facebook Twitter Email
Craig M Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology and director of the Pathology Core Facility at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study published in Blood.

Northwestern Medicine scientists have developed a new tool to help physicians predict the risk of venous thromboembolism in patients with adult-type diffuse gliomas, results published in the journal Blood.

Venous thromboembolisms (VTE), blood clots that form in veins, can be life-threatening for patients with adult‐type diffuse gliomas, the most common type of malignant tumor arising in the brain.

To create the risk prediction tool, investigators analyzed arterial blood, tumor tissue and other data from 483 patients with newly diagnosed adult-type diffuse glioma.

They found seven factors which predicted increased risk of VTE in those patients: prior history of VTE, hypertension, asthma, elevated white blood cell count, higher glioma grade, increasing patient age and elevated body mass index.

Conversely, investigators found that mutations in IDH1 or IDH2 genes, hypothyroidism, and MGMT gene inactivation all predicted a reduced risk of VTE.

Those ten variables were then combined to create a novel web-based VTE prediction tool, said Craig M Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology, director of the Pathology Core Facility at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and senior author of the study.

“For the first time, we have an evidence-based prediction of venous thromboembolism specifically for glioma patients,” he said. “This tool is a web-based calculator. You enter in basic information about the patient and tumor, and get a percent of risk at one, three, six and 12 months.”

Armed with that information, physicians can weigh the risk of a clot against other risks that come with preemptively administering anticoagulants, which can sometimes cause brain hemorrhages, Horbinski said.

“When I informally polled physicians on how they assess the risk of these blood clots, I got various answers,” Horbinski said. “It all depends on how aggressive they are about anti-thrombotic prophylaxis. Physicians can give patients heparin up front but often would not know if a particular patient was really at risk of a blood clot or not. Plus, heparin administration is painful and may increase the risk of bleeding in the brain. Before now, there’s just never been rigorous evidence to guide that decision-making.”

Now, Horbinski said he is planning to conduct a trial with high-risk patients to further validate the tool and provide better guidance on which patients would benefit the most from preventative anticoagulants.

The study was supported by NIH grants R01NS102669, R01NS117104, R01NS118039, the Northwestern University SPORE in Brain Cancer P50CA221747, and the Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Lurie Cancer Center.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Comments are closed.

Latest News

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.